Who are IGIV GAMMAGARD LIQUID/KIOVIG's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PRIVIGEN (CSL Behring), IGIV3I Grifols, IgNextGen 16%, IV treatment with IGSC, 10%, Gamunex Intravenous Immunoglobulin, IGIV GAMUNEX®-C.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/igiv-gammagard-liquid-kiovig.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

IGIV GAMMAGARD LIQUID/KIOVIG — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IGIV GAMMAGARD LIQUID/KIOVIG (IGIV GAMMAGARD LIQUID/KIOVIG) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intravenous immunoglobulin (IGIV). Area: Immunology.

phase 3 Intravenous immunoglobulin (IGIV) Fc receptors, complement system, pathogenic antigens Immunology Biologic Live · refreshed every 30 min

Target snapshot

IGIV GAMMAGARD LIQUID/KIOVIG (IGIV GAMMAGARD LIQUID/KIOVIG) — Baxalta now part of Shire. IGIV (intravenous immunoglobulin) provides passive immunity by supplying pooled human antibodies to replace or supplement deficient or dysfunctional immunoglobulin in patients with immune deficiencies or autoimmune conditions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IGIV GAMMAGARD LIQUID/KIOVIG TARGET	IGIV GAMMAGARD LIQUID/KIOVIG	Baxalta now part of Shire	phase 3	Intravenous immunoglobulin (IGIV)	Fc receptors, complement system, pathogenic antigens
PRIVIGEN (CSL Behring)	PRIVIGEN (CSL Behring)	Hospices Civils de Lyon	marketed	Intravenous immunoglobulin (IVIg)	Fc receptors, complement system, pathogenic antigens and antibodies
IGIV3I Grifols	IGIV3I Grifols	Instituto Grifols, S.A.	phase 3	Intravenous immunoglobulin (IVIG)	Fc receptors, complement system, pathogenic antigens
IgNextGen 16%	IgNextGen 16%	CSL Limited	phase 3	Intravenous immunoglobulin (IVIG)	Fc receptors, complement system, pathogenic antigens
IV treatment with IGSC, 10%	IV treatment with IGSC, 10%	Baxalta now part of Shire	phase 3	Immunoglobulin replacement therapy	Fc receptors, complement system, pathogenic antigens
Gamunex Intravenous Immunoglobulin	Gamunex Intravenous Immunoglobulin	National Institute of Mental Health (NIMH)	phase 3	Intravenous Immunoglobulin (IVIG)	Fc receptors, complement system, pathogenic antigens
IGIV GAMUNEX®-C	IGIV GAMUNEX®-C	Baxalta now part of Shire	phase 3	Intravenous immunoglobulin (IVIG)	Fc receptors, complement system, pathogenic antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Intravenous immunoglobulin (IGIV) class)

Baxalta now part of Shire · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IGIV GAMMAGARD LIQUID/KIOVIG — Competitive Intelligence Brief. https://druglandscape.com/ci/igiv-gammagard-liquid-kiovig. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab